Calporta develops selective small molecule agonists to transient receptor potential cation channel, mucolipin subfamily, member 1 (TRPML1), also ... $495 million Avalon-GSK collaboration, with ...

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain. Avalon Ventures and GlaxoSmithKline set Calporta up in 2015 as ...

Calporta was founded in 2015 at COI Pharmaceuticals, a start-up incubator funded by GlaxoSmithKline and the ... are small-molecule agonists of TRPML1, a calcium channel found in lysosomes, the ...

They found that zinc permeability of TRPML1 played a critical role in the process. "When we tested different ion blockers to see which could prevent the cell death, we found that if we blocked ...

Caraway’s Chief Executive Officer, Martin D. Williams, will present recent advances in the Company’s TRPML1 program at the Fall Life Sciences Private Company Showcase, co-hosted by BMO Capital ...